Welcome to our dedicated page for Zimmer Biomet Holdings news (Ticker: ZBH), a resource for investors and traders seeking the latest updates and insights on Zimmer Biomet Holdings stock.
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) is a preeminent global leader in musculoskeletal healthcare. Headquartered in Warsaw, Indiana, Zimmer Biomet has been at the forefront of advancing bone and joint health for nearly 90 years. The company designs, manufactures, and markets a comprehensive range of orthopedic implants and surgical equipment, addressing joint reconstruction, bone repair, sports medicine, spine, and dental reconstruction. Its innovative product portfolio includes the ROSA® Robotics systems for knee, hip, and shoulder replacements, and the TMINI Miniature Robotic System for total knee arthroplasty.
Zimmer Biomet's latest endeavors include the establishment of a dedicated Health Equity division in 2023, which aims to integrate health equity into the company's core strategies and operations. This division has already made significant strides by assembling a strategic advisory board and developing the Community Centered Care (C3) framework to increase patient access to quality care in underserved communities.
In addition, Zimmer Biomet has recently partnered with top pickleball organizations in the U.S., underscoring its commitment to joint health and well-being for the growing community of pickleball players. The company also announced a strategic alliance with CBRE Group, Inc. to expand orthopedic ambulatory surgery centers across the country, and a collaboration with RevelAi Health to commercialize AI-powered engagement solutions aimed at advancing value-based orthopedic care and health equity.
Financially, Zimmer Biomet has demonstrated robust performance, with first-quarter 2024 net sales amounting to $1.889 billion, a 3.2% year-over-year increase. The company continues to focus on innovation, operational excellence, and strategic partnerships to drive growth and enhance shareholder value. For more information, visit www.zimmerbiomet.com or follow them on LinkedIn and Twitter.
Zimmer Biomet's recent one-year study confirms that the mymobility platform using Apple Watch provides comparable outcomes to traditional care for knee replacement patients. The study, involving 401 patients, indicates significant reductions in outpatient physical therapy visits and emergency department visits related to surgery. Key results include a 60.6% rate of post-operative PT among mymobility users versus 94.6% in the control group, and a 1.3% surgery-related ED visit rate compared to 5.4% for controls. These findings, presented at the AAHKS annual meeting, may suggest cost-saving potential in patient care.
Zimmer Biomet reported Q3 net sales of $1.670 billion, down 0.9% but up 5.0% on a constant currency basis. Diluted EPS from continuing operations was $0.92, while adjusted diluted EPS was $1.58. The company raised its 2022 financial guidance, with projected revenue growth tightened to 0%-1% and adjusted diluted EPS forecasted at $6.80-$6.90. Notable developments include an AI partnership with Hospital for Special Surgery and FDA clearance for the Identity Shoulder System.
The 13th Annual National Caucus, organized by Movement is Life, will take place on November 10-11, 2022, in Washington, DC. This event aims to address joint pain and health disparities involving patients, community leaders, and healthcare providers. Zimmer Biomet, the founding partner, is making a multi-million-dollar commitment to support initiatives like The Value Project and Operation Change to enhance health equity. The caucus seeks to develop actionable plans to tackle barriers affecting those with joint pain, particularly among marginalized groups.
Zimmer Biomet Holdings (ZBH) will host its third quarter earnings conference call on November 2, 2022, at 8:30 a.m. ET. A detailed news release regarding the quarterly results will be published that same day at 6:30 a.m. ET. Investors can access the live audio webcast via Zimmer Biomet's Investor Relations website, which will also archive the call for later playback. Participants can join the call by dialing (888) 312-9837 and using conference ID 7278985.
Zimmer Biomet (ZBH) announced FDA 510(k) clearance for its Identity™ Shoulder System, designed for anatomic, reverse, and revision shoulder replacements. This system allows surgeons to tailor surgical plans to individual patient anatomy, aiming to enhance pain relief and range of motion. The innovative design provides eight humeral tray combinations and 5mm additional joint space for possible future revisions. With this clearance, Zimmer Biomet strengthens its Sports Medicine and Extremities portfolio, reinforcing its position as a leader in medical technology.
Zimmer Biomet announced a multi-year co-marketing agreement with Surgical Planning Associates to commercialize HipInsight™, the first FDA-cleared mixed reality navigation system for hip replacements. Using Microsoft HoloLens 2, surgeons can visualize patient-specific anatomy during procedures, enhancing accuracy in implant placement. This technology integrates with Zimmer Biomet's hip implant portfolio and aims to improve surgical outcomes. The partnership highlights Zimmer Biomet's commitment to innovative medical technology.
Zimmer Biomet Holdings (ZBH) will present at the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, at 10:30 a.m. ET, and at the J.P. Morgan 13th Annual U.S. All Stars Conference on September 20, 2022, at 9:00 a.m. ET. The presentations will be available via a live webcast on Zimmer Biomet's Investor Relations website, with recordings accessible afterward. Zimmer Biomet is known for its innovative medical technology solutions aimed at improving patient mobility and health, supported by over 90 years of industry leadership.
Zimmer Biomet announced a quarterly cash dividend of $0.24 per share for Q3 2022, payable on October 31, 2022. This dividend will benefit stockholders of record as of September 30, 2022, demonstrating the company's commitment to returning value to its shareholders. The company continues to position itself as a leader in the medical technology sector, focusing on enhancing patient experiences through innovation.
Zimmer Biomet reported Q2 2022 net sales of $1.782 billion, a 1.0% increase year-over-year and a 6.0% rise on a constant currency basis. Diluted EPS was $0.73, with adjusted EPS at $1.82. The company attributed its performance to a stronger-than-expected COVID recovery and strategic execution. Full-year 2022 guidance was raised, now forecasting revenue change between (1.0)% and 1.0% and adjusted diluted EPS of $6.70 to $6.90. The launch of AI capabilities in their Omni Suite was also highlighted.
Zimmer Biomet (ZBH) and Hospital for Special Surgery (HSS) have announced a three-year collaboration to establish the HSS/Zimmer Biomet Innovation Center for Artificial Intelligence in Robotic Joint Replacement. This first-of-its-kind partnership will focus on developing AI-based decision support tools for robotic-assisted joint surgeries, enhancing clinical outcomes through data-driven insights. The initiative leverages the expertise of HSS and Zimmer Biomet's robotics and AI capabilities, integrating these tools into their ROSA system to improve patient care.
FAQ
What is the current stock price of Zimmer Biomet Holdings (ZBH)?
What is the market cap of Zimmer Biomet Holdings (ZBH)?
What does Zimmer Biomet do?
Where is Zimmer Biomet headquartered?
What are Zimmer Biomet's latest innovations?
What is Zimmer Biomet's focus on health equity?
How did Zimmer Biomet perform financially in the first quarter of 2024?
What are Zimmer Biomet's partnerships?
What is the ROSA® Robotics system?
What is the Community Centered Care (C3) framework?
What is Zimmer Biomet's role in pickleball?
How does Zimmer Biomet contribute to innovation in healthcare?
